15 April 2021 1 Min Read
EMA reviewing GSK’s monoclonal antibodies to treat Covid-19
Early data shows an 85% reduction in risk of hospitalisaton and death, with similar treatment types already used against some cancers
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In